50,671 Shares in Axsome Therapeutics, Inc. $AXSM Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the second quarter, according to its most recent filing with the SEC. The firm bought 50,671 shares of the company’s stock, valued at approximately $12,403,000.

Several other institutional investors have also recently bought and sold shares of AXSM. Kemnay Advisory Services Inc. bought a new stake in Axsome Therapeutics during the fourth quarter valued at about $31,000. Ameriflex Group Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth about $37,000. Hollencrest Capital Management increased its stake in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after purchasing an additional 160 shares during the period. Silvant Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth about $66,000. Finally, Farther Finance Advisors LLC boosted its stake in Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after purchasing an additional 235 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $207.77 on Monday. The business has a 50 day moving average price of $232.13 and a two-hundred day moving average price of $206.16. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics, Inc. has a 12 month low of $112.90 and a 12 month high of $260.19. The stock has a market cap of $10.88 billion, a price-to-earnings ratio of -55.41 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The firm had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. BMO Capital Markets assumed coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Friday, July 17th. Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a research report on Monday, May 4th. Zacks Research upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Finally, UBS Group assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, August 11th. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.60.

Insider Buying and Selling

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This represents a 39.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Susan Mahony sold 300 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the transaction, the director owned 1,129 shares of the company’s stock, valued at $267,810.09. This trade represents a 20.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 200,766 shares of company stock worth $46,685,646 in the last three months. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.